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ABSTRACT 
OBJECTIVE:  The objective of this systematic review is to determine whether 
Esomeprazole (Nexium) is more safe and effective than Omeprazole (Prilosec) in 
reducing Heartburn and in increasing the rate of esophageal healing in adults with 
endoscopically diagnosed Erosive Esophagitis (EE) 
STUDY DESIGN: A review of all English language randomized controlled double 
blind comparative trials comparing the different forms of Proton Pump Inhibitors 
from 2006-2009.  The studies included participants 18-85 years old with GERD and 
endoscopically diagnosed Erosive esophagitis. 
DATA SOURCES:  Randomized controlled Double Blind Comparative trials were 
Found using PubMed and Cochrane Databases. 
OUTCOME MEASURED: Outcomes measured were reduction in GERD symptoms and 
healing of erosive esophagitis.  Each Article measured symptoms based off of patient 
daily journals and symptoms criteria scales.  Measurement of esophageal healing was 
done based off of the LA Classification scale.  One article measured reduction of GERD 
symptoms after 5 days of treatment and the other two measured reduction after 4 weeks 
of treatment.  Patients whos GERD symptoms were measured after 5 days of treatment 
were assessed based on a 6 point symptom scale (0: none; 1: mild; 2: mild-moderate; 3: 
moderate; 4: moderate-severe; 5: severe and/or intolerable). 
RESULTS:  All three RCTs in this review found that there were comparable effect on 
GERD Symptoms both after 4 weeks of treatment and after 5 days of treatment.  One 
RCT found that Esomeprozole more rapidly decreased GERD symptoms compared 
to other PPIs but after 5 days showed no difference in efficacy.  All trials also found 
that 40mg and 20 mg of Esomeprozole showed no significant difference in  EE 
Healing compared with Omeprozole 20mg.   
CONCLUSION:  The Results of the three RCTs showed evidence that Esomeprozole  
was just as effective as Omeprozole 20mg after 7 days of treatment but had no 
difference in efficacy after 4 and 8 weeks of treatment.  There was no evidence 
found that Esomeprozole had greater efficacy on Esophageal healing at 8 weeks 
with 20mg and 40 mgs compared to Ompeprozole 20mg.   
KEYWORDS:  Omeprozole, Esomeprozole, Erosive Esophagitis, GERD 
 
 
 
 
                                                        Mahoney, “Esomeprozole vs. Omeprozole” 
 
3 
 
 
Introduction: 
GastroEsophageal Reflux Disease or GERD is a very common disease of the 
upper GI system that affects about 10-40% of the adult US population.  If not treated 
this disease can progress into other serious conditions such as erosive esophagitis 
(EE), Barrots Esophagus and even Esophageal Cancer.  In fact about 40-60% of 
patients with GERD will progress to these other serious conditions.  Fortunately 
these subsequent diseases can be prevented with daily medication such as proton 
pump inhibitors with a prescription from your primary care practitioner.   Not only 
would this medication be beneficial to prevent symptoms and disease progression 
but it would also reduce the cost that GERD has on society as a whole.  Currently 
GERD and its associated diseases is costing American businesses $75 billion per 
year in workforce productivity due to the 16 million people scheduling doctors 
appointments and diagnostic procedures, keeping people from work; not to mention 
the amount Americans spend on treatment and diagnostic studies alone. 
GERD results when there is weakening and relaxation of the lower 
esophageal sphincter leading to gastric contents to enter the esophagus.  As a result 
the acidic contents of the stomach causes irritation and erosion of the esophageal 
lining.  Over time this erosive esophagitis may lead to Barrot’s esophagus  in which 
the lining of the esophagus goes through histologic changes from squamous cells to 
columnar cells.  Individuals with barrots are more prone esophageal cancer as a 
result of this histologic change.  All of these issues could easily be avoided by many 
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preventable measures such as measures such as weight loss, change in eating habits, 
smoking cessation and elevating the head while sleeping.   
Though all of these measures help in reducing GERD symptoms not one of 
them measures up to the effectiveness of PPIs such as Esomeprozole (Nexium) or 
Omeprozole (Prilosec).  PPIs work to reduce the amount of HCL produced by the 
parietal cells of the stomach, ultimately reducing the acidity of the stomach and as a 
result reducing acid reflux symptoms.   
Since PPIs have been developed there have been multiple additions to the 
PPI family such as esomeprozole, lansoprozole and Pantoprozole to name a few.  
With each new one created there is question of their efficacy when compared to the 
others. A prime example is the difference between the safety and efficacy of 
Esomeprozole and Omeprozole in treating GERD and GERD related diseases.  The 
answer to this question is beneficial because Omeprozole is often a cheaper 
alternative to Esomeprozole.  In order to answer this question a systematic review 
was conducted, comparing three RCTs.  The SR was done to determine if there is a 
difference in safety and efficacy in relieving GERD symptoms and in the healing of 
erosive esophagitis. 
Objective:  
The objective of this systematic review is to determine whether 
Esomeprazole (Nexium) is more safe and effective than Omeprazole (Prilosec) in 
reducing Heartburn and in increasing the rate of esophageal healing in adults with 
GERD and endoscopically diagnosed Erosive Esophagitis (EE). 
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Method: 
 All three trials selected for this systematic review included randomized 
controlled trials (RCTs) with adult patients anywhere from 18-85 years old (age 
range depending on study) who have been endoscopically diagnosed with Erosive 
Esophagitis (EE).  Each study included an intervention of Esomeprozole 20-40mg 
QD, using Omeprozole 20mg QD as the control group.  Some variation did exist 
between studies.   Although all three trials endoscopically measured the difference 
in the healing of EE after 8 weeks and the reduction of GERD symptoms, specifically 
heartburn. Two of the studies had treated patients for 8 weeks and one of the 
studies for only 7 days.  Also, the two 8 week trials measured effects on heartburn 
after 4 weeks of treatment and the 7 day study measured the effects on heartburn 
every day up until day 5 of treatment.  Further specific variations in study are 
mentioned below. 
In the Lightdale, 2006 study, the experimental group was given 
Esomeprozole 20mg QD for 8 weeks and the control group was given omeprozole 
20mg QD for 8 weeks.   The study measured the patients change in GERD symptoms 
at 4 weeks but measured the rate of Esophageal healing at 4 and 8 weeks.  The 
Schmitt 2006 study was conducted in the exact same format except that 
Esomeprozole 40mg was used as the experimental treatment instead of 
Esomeprozole 20mg. 
The Zheng 2009 study was conducted in a slightly different fashion.  The time 
frame of this study was 7 days in duration with results recorded using the acid 
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reflux score; specifics of this scoring system can be found in the “Outcomes 
Measured” section.  Scores were recorded on days 1 through 5 using Esomeprozole 
40mg QD as the experimental group and Omeprozole 20mg as the control group.  
Pantoprozole and Lansoprozole were also used in this trial as experimental groups 
but these results were disregarded from the review for simplicity sake. 
All three article were English speaking and have been written in peer 
reviewed journals.  Keywords used in the literature search Esomeprozole, 
Omeprozole, GERD and Erosive Esophagitis using PubMed and Chochrane 
Databases to perform the search.  Articles were excluded if not POEMs, RCTs, 
written before 2005 and if it did not include symptom based outcomes.  Statistics 
used in the studied included P values, RRR, ARR NNT and CI. 
Outcomes Measured: 
Outcomes measured were reduction in GERD symptoms and healing of erosive 
esophagitis.  Each Article measured symptoms based off of patient daily journals and 
symptoms criteria scales.  Measurement of esophageal healing was done based off of the 
LA Classification in all three the articles.  One article measured reduction of GERD 
symptoms after 5 days of treatment and the other two measured reduction after 4 weeks 
of treatment.  Patient participants of the 7 day treatment were assessed based on a 6 point 
subjective symptom scale (0: none; 1: mild; 2: mild-moderate; 3: moderate; 4: 
moderate-severe; 5: severe and/or intolerable). 
Table 1 - Demographics & Characteristics of included studies  
Study Type #Pt Age(y Inclusion Exclusion W/ Intervent
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s rs) criteria Criteria D ions 
Lightda
le, C.J.; 
2006 
A 
Multicenter, 
Randomized, 
Double-Blind, 
8-Week 
Comparative 
117
6 
18-65 an 
endoscopic 
diagnosis 
of erosive 
essophagiti
s that 
tested 
negative 
for H. 
pylori 
positive for H. 
pylori by 
serology at 
screening; GI 
bleeding 
detected at the 
time of the; and 
a H/O of gastric 
surgery. H/O of 
Zollinger-
Ellison 
syndrome. 
esophageal 
motility 
disorder, 
stricture, or any 
serious medical 
condition, 
including 
cancer and 
Barrett’s 
esophagus. 
70 Daily 
Administ
ration of 
Esomepr
azole 
20mg for 
4-8 
weeks 
and Daily 
Administ
ration of 
Omepraz
ole 20mg 
for 4-8 
weeks 
Schmitt
, C; 
2006 
A 
Multicenter, 
Randomized, 
Double-Blind, 
8-Week 
Comparative 
Trial 
 
 
114
8 
18-65 an 
endoscopic 
diagnosis 
of erosive 
essophagiti
s that 
tested 
negative 
for H. 
pylori 
Same as 
Lightdale, C.J. 
2006 
publication 
28 Esomepr
azole 
20mg QD 
for 4-8 
weeks 
and 
Omepraz
ole 20mg 
QD for 4-
8 weeks 
Zheng, 
R.N.;20
09 
Randomized 
comparative 
study based 
on efficacy 
and safety of 
treatment on 
all 4 
medications. 
 
274 36-85 endoscopi
cally 
diagnosed 
reflux 
essophagi
tis 
Active PUD, 
upper GI 
CA, CA of 
other 
organs, 
cardiac, 
hepatic, or 
renal 
diseases, 
anemia, 
pregnant 
and/or 
lactating. 
 
10 Pts to 
receive 
either 
40mg QD 
Esomepr
azole X 8 
weeks or 
20mg QD  
Omepraz
ole for 8 
weeks 
 
Results: 
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 This Systematic review was done on three randomized controlled trials; two 
of which were 8 week comparative trials and one a 7 day trial.  All three included 
omeprozole 20 mg daily as the control and esomeprozole as the experimental dosed 
at either 20mg or 40 mg daily.  Patients included in each study were between the 
ages of 18-85 and endoscopically diagnosed with Erosive Esophagitis.  All 
participants were tested for H. Pylori and were only included in the study if test 
results came back negative for H. Pylori.   
 In the Lightdale, 2006 study, after 4 weeks there was found to be no 
significant difference in efficacy between the two PPIs in resolving heartburn 
(p=0.995); Esomeprozole having 60.6% efficacy and Omeprozole 60.5% efficacy.  
Similarly the difference between the two treatments found no statistical significance 
in EE healing after 8 weeks (p=0.621); with Esomprozole being 90.6% effective and 
Omeprozole being 88.3% effective. 
 The Schmidt 2006 study, similar data was collected that found no statistical 
significance between the experimental and the control group.  At 4 weeks, 
Esomeprozole 40mg was 65.0% effective and Omeprozole 20mg was 63.1% 
effective with a P-value of 0.480.  Similarly, At 8 weeks, there was no statistical 
significance on the rate of EE healing for either treatments (p=0.552); Esomeprosole 
40mg being 92.2% effective and Omeprozole 20mg being 89.8% effective. 
The Zheng 2009 study concluded that during the first few days of treatment 
some variation  existed on GERD symptom reduction showing that Esomeprozole 
was of greater efficacy than Omeprozole.  By day 5 there was no statistical 
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difference in efficacy between the two treatments (p=0.0069).  After 8 weeks 
patients were brought back in for endoscopic measurement of EE healing.  
Endscopic results showed that there was no statistical difference in the rate of 
esophageal healing between the two treatments (esomeprozole at 95.4% and 
Omeprozole at 87.7%).   
Table 2: Esomeprozole vs. Omeprozole on the reduction of GERD symptoms. 
 Esomeprozole 
(EER) 
Omeprosole  
(CER) 
P Value RBI ABI NNT 
Lightdale, 
2006  
(4 
weeks) 
60.6% 60.5% 0.995 0.00165 0.001 1000 
Schmidt, 
2006 
(4 
weeks) 
65.0% 63.1% 0.48 0.0292 0.019 52.6 
Zheng, 
2009  
(5 days) 
N/A N/A 0.0069 N/A N/A N/A 
 
Table 3: Esomeprozol vs. Omeprozole in Esophageal healing at 8 weeks of 
treatment. 
 Esomeprozol 
(EER) 
Omeprosole 
(CER) 
P Value RBI ABI NNT 
Lightdale, 
2006  
(8 
weeks) 
90.6% 88.3% 0.621 0.026 0.023 43.5 
Schmidt, 92.2% 89.8% 0.552 0.027 0.024 41.7 
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2006 
(8 
weeks) 
Zheng, 
2009  
(5 days) 
95.4% 87.7% N/A 0.088 0.077 12.99 
 
To understand why the authors of the article deemed the differences 
between each treatment stastistically insignificant the RBI, ABI and NNT were 
calculated for each study.  This was done by taking the efficacy rates for each 
treamtment; Esomeprozole being the Experimental Event Rate (EER) and 
omeprozole being the Controled Event Rate (CER).  Both were used to calculate the 
Relative Benefit Increased (RBI) and the Absolute Benefit Increase (ABI).  The ABI 
was then used to calculate Numbers Needed to Treat (NNT).  Numbers needed to 
treat will tell us how many patents need to be treated in order to have 
Esomeprozole show some statistical significance in efficacy over Omeprozole.   
In Lightdales study, in order for Esomeprozole to have show significant 
benefit over Omeprozole for treating heartburn about 1000 people would need to 
be treated and about 43.5 people would need to be treated to show a benefit for EE 
healing.  In the Schmidt 2006 study, 52.6 patients would need to be treated to show 
a greater benefit in heartburn treatment and 41.7 for EE healing.  The Zheng 2009 
study, it wasn’t possible to calculate NNT for Heartburn treatment but it did show 
that Esomeprozole was slightly more beneficial than Omeprozole with an NNT of 
12.99. 
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Safety: Only the Lightdale 2006 and Schmidt 2006 studies documented 
Adverse Effects of their treatments. Both studies showed similar results in safety 
between the experimental and control.  Four of the most common side effects of 
both drugs were HA, Gastritis, Diarrhea and Respiratory infection.  In both studies, 
Esomeprozole and Omeprozole yielded similar percentages in Adverse Effects(AE) 
with Esomeprozole having slightly higher incidences of AE in all types.  Specific 
numbers and percentages can be found in tables 4 and 5.  Despite a few Adverse 
side effects reported by some patients overall the two drugs were very well 
tolerated during the study. 
Table 4: Common Adverse Effects of Esomeprozole and Omeprozole from 
Lightdale 2006. 
 Headaches Gastritis Diarrhea Resp. 
Infection 
Esomeprozole 58 (9.9%) 31 (5.3%) 27 (4.6%) 27 (4.6%) 
Omeprozole 37 (6.3%) 18 (3.1%) 28 (4.8%) 25 (4.3%) 
 
Table 5: Common Adverse Effects of Esomeprozole and Omeprozole from 
Schmidt 2006 Study 
 Headaches Gastritis Diarrhea Resp. 
Infection 
Esomeprozole 59 (10.2%) 28 (4.9%) 38 (6.6%) 26 (4.5%) 
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Omeprozole 39 (6.8%) 18 (3.2%) 31 (5.4%) 16 (2.8%) 
 
Discussion: 
 Historically PPIs are very safe and effective drugs used to treat GERD and 
other gastric diseases such as ulcers and H. Pylori infections.  These studies have 
indicated that PPIs are also effective in treating Erosive Esophagitis.   EE is a disease 
that is often a result of chronic GERD and heartburn.  As a result of these 
observations, it can be hypothesized that aggressive treatment of GERD with PPI 
therapy ultimately reduces the damaging affects of GERD on the esophagus and 
allows for prevention and quicker healing of erosive esophagitis.   
 Other similar studies may be performed to test this hypothesis and to 
provide more concrete evidence that PPI therapy is a safe and effective treatment 
for erosive esophagitis.  If enough evidence is collected,  it will be easier to educate 
patients on the effectiveness  of PPI therapy an adequate preventative treatment of 
erosive esophagitis and other diseases caused by GERD.  This type of preventive 
measure would not only reduce the uncomfortable and dangerous problems 
individual patients have with Esophageal disease.  It can also reduce the amount of 
money American spends each year on GERD and  related diseases. 
Conclusion: 
 After reviewing all three articles and comparing the results, it has been 
concluded that there is no overall, statistically significant difference between 
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Esomeprozole and Omeprozole for the treatment of GERD symptoms or for EE 
Healing.  From the Zheng 2009 study results, it is possible that Esomeprozole might 
provide reduction GERD symtoms quicker than Omeprozole in the first 1-2 days of 
treatment; but by the 5th day of treatment, Omeprozole was fount to be just as 
effective as Esomeprozole in symptom reduction.  In light of these findings, it would 
be beneficial to perform more 7 day trials of PPI treatment to determine if these 
findings are credible and to determine if Esomeprozole would be a better choice if 
one was looking for the quickest way to successfully reduce GERD symptoms. 
It was mentioned in Lighdale 2006 study that when comparing the healing 
rate of 4 and 8 weeks, the rate of esophageal healing although, not significant at 8 
weeks, was beginning to approach significance.  This opens up the possibility that, if 
given for a longer duration, Esomeprozole could show a significant difference in 
efficacy with regards to esophageal healing rates compared to Omeprozole.  It would 
be beneficial to "attempt this experiment again for a longer period of time; for about 
12 to 16 weeks.   
 After reviewing the methods section of each article it was noted that certain 
variable that were not controlled for and may be beneficial in future studies to more 
definitively confirm the similar efficacy of these two medications.  One specific 
variable is the dietary habits of the participants.  There was no mention of control in 
the patients dietary habits.  This could have had an impact on GERD symptom 
presentation and exacerbations of participants.  In order to control for this it would 
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be beneficial to put all participants on a diet restricting individuals from foods 
known to exacerbate GERD symptoms.   
 In conclusion It has been determined by this systematic review that both 
Esomeprozole and Omeprozole are equally safe and effective in treating GERD 
symptoms and for improving the rate of EE healing.  If patients propose that the 
cannot afford the more expensive esomeprozole then the physician can offer the 
alternative of the cheaper Omeprozole to the patient.  The Physician should explain 
to the patient that Omeprozole may not be as effective in the first few days but if 
given time is just as safe and effective as its more expensive counterpart.   
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